# NDRA earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/NDRA) · [Earnings tab](https://www.lopjlb.com/stock/NDRA?tab=earnings)

Updated: 2026-11-14T06:37:56

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards ENDRA moved from early data‑collection and cash‑rich positioning to a prolonged regulatory timeline and tighter liquidity. In late‑2022 the company reported growing scan volumes, delivery of interactive guidance software and an on‑track FDA de novo filing, while expanding its patent estate to 56 families. 2023 saw the completion of clinical data, a formal de novo submission and a shift to Europe‑first commercialization, with the patent count rising to 75 and cash dwindling to the low‑single‑digit‑million range. 2024 introduced a new clinical‑trial focus, a mid‑2025 de novo target, aggressive cost cuts and a capital raise that restored runway to early‑2025, but also a reverse‑split execution that was later undermined by warrant activity. Throughout, operator variability and regulatory timing remained prominent concerns, while partnership reliance on GE faded and the company’s market focus broadened beyond radiology. The narrative reflects a transition from rapid early‑stage execution to a more cautious, capital‑constrained phase emphasizing regulatory strategy, trial execution and IP depth.

## Latest CallCard · Q2

ENDRA Q2 2024: reverse split derailed by warrant exercises; new team prioritizes multi-center clinical trial for TAEUS liver device, targets de novo submission mid-2025; cash runway into H1 2025; expenses cut 26%.

**Guidance:** vague — No formal financial guidance provided; clinical timeline targets: complete clinical study 2024, initiate pivotal early 2025, de novo submission mid-2025.

**Tone:** mgmt 0.1 · Q&A pressure 0.2 · divergence 0.3

Management acknowledges reverse split derailed by warrant exercises but emphasizes new leadership, clinical trial prioritization, FDA alignment, and cost reductions as positive steps.

### Demand visibility

Limited visibility; shifting focus from hepatology to primary care/other segments; no quantified demand metrics.

Management indicates hepatology may not be primary target market; exploring primary care and other segments; clinical data needed to demonstrate value proposition to clinicians and pharma.

### Margins / costs

Operating expenses reduced 26% annually ($3M+); R&D down 49%, sales & marketing down 34%; further cost scrutiny planned.

Q2 2024 total operating expenses $2.2M vs $3M YoY; R&D decreased $684K as shift from development to clinical; European ops restructured; G&A increased $5K due to fundraising costs; management expects further expense structure adjustments.

### Capital allocation

Raised $7.3M in public offering; cash $6.4M provides runway into H1 2025; capital allocated to clinical trial execution and regulatory submission.

Net proceeds from June public offering $7.3M; cash equivalents $6.4M at June 30; runway into first half 2025; spending prioritized on multi-center clinical trial and de novo preparation; operating expense reductions of 26% annualized to extend runway.

### Milestones

- **Reverse stock split (1-for-50)** [delivered]: Effective but stock price below $1 due to high warrant exercise volume from June public offering.
- **Strengthen operating team** [delivered]: New CFO Richard Jacroux and Head of Regulatory/Clinical Ziad Rouag joined; CTO Mike Thornton continues.
- **Relentless prioritization on clinical trial** [on_track]: Pilot data acquired on 25 subjects across 3 sites (2 US, 1 EU); pivotal trial design pre-vetted with FDA.
- **New FDA regulatory strategy** [on_track]: Switch to prospective, statistically-powered multi-center trial with ~250 subjects; FDA alignment on product configuration, study design, pathway.
- **Go-to-market strategy revision for TAEUS liver device** [new]: Hepatology may not be beachhead; exploring primary care and other segments over next 6-12 months.
- **Crystallize Android vision (metabolic disease biomarker company)** [new]: Strategic roadmap to be developed over next 12 months; includes organic growth and licensing opportunities.
- **Improved financial stewardship** [delivered]: Achieved 26% annualized operating expense reduction ($3M+) without impacting clinical data collection.
- **FDA meeting alignment** [delivered]: Meeting minutes confirmed alignment on final product configuration, clinical study design, and regulatory pathway.

## Quarter one-liners

- **2024 Q2:** ENDRA Q2 2024: reverse split derailed by warrant exercises; new team prioritizes multi-center clinical trial for TAEUS liver device, targets de novo submission mid-2025; cash runway into H1 2025; expenses cut 26%.
- **2024 Q1:** ENDRA advances clinical evidence in UK/US, prepares FDA de novo pre-submission meeting, leverages Rezdiffra-driven market tailwinds, expands IP portfolio to 80 patents, but cash limited at $1.1M.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights milestones achieved (UK installation, FD
- **2023 Q4:** ENDRA advances FDA De Novo for TAEUS with Q2 pre-sub meeting, activates UK clinical site at King's College, expands IP portfolio to 75 patents, targets European commercialization in 2024, and evaluates capital raise with $2.8M cash.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management highlights pro
- **2023 Q3:** ENDRA submitted TAEUS de novo to FDA (150-day review), reported strong clinical data (0.87 correlation vs MRI), focuses on Europe commercialization first with CE mark, cash runway into Q1 2024, raising capital.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Management emphasizes clinical and regulatory m
- **2023 Q2:** ENDRA submitted FDA de novo for TAEUS liver system with promising clinical data; expects first Europe sales by year-end; cash runway into Q4 2023.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management emphasizes pivotal milestone of FDA de novo submission, strong clinical data (R-value 0.78, sensitiv
- **2023 Q1:** ENDRA completed clinical data collection for FDA de novo submission of TAEUS liver fat measurement, plans midyear filing, raised $4.5M post-quarter, and sees broader European market beyond radiology. Runway extended to Q4 2023. Clinical abstract accepted for EASL Congress June 2023. Patent portfolio
- **2022 Q4:** ENDRA highlighted progress on TAEUS clinical scans and a new software guidance tool that improved operator performance, while preparing a de novo FDA submission, renewing its GE partnership and expanding its patent portfolio despite a longer‑than‑expected timeline.
- **2022 Q3:** ENDRA reports 95 TAEUS scans YTD, progressing toward FDA de novo submission with user guidance tools; $8M cash runway; Europe commercialization via rental/lease models; 56 patents issued.

## Theme arcs

- **Regulatory progress** (deteriorating): Initial on‑track filing became delayed, now targeting mid‑2025 instead of 2023‑24
- **Cash position** (deteriorating): Cash fell from $8M (2022 Q3) to $1.1M (2024 Q1) before a $7.3M raise extended runway to H1 2025
- **Operator variability mitigation** (improving): Guidance software delivered in 2022 Q4 reduced intra‑operator differences
- **Patent portfolio** (improving): Patents grew from 56 (2022 Q3) to 80 (2024 Q1)
- **Market focus** (new): Shift from radiology‑centric to broader primary‑care and metabolic disease segments in 2024 Q2
- **Partner dependence** (resolved): GE partnership renewal noted in 2022 Q4 but not referenced later
- **Commercialization timeline** (deteriorating): Europe launch moved from expected 2023 year‑end to 2024 and beyond
- **Stock actions** (new): Reverse split executed in 2024 Q2 but its effect was negated by warrant exercises

## Fear persistence

- **Regulatory risk** [recurring]: Timeline uncertainty noted from 2022 Q3 through 2024 Q2
- **Operator variability** [recurring]: User performance concerns raised 2022 Q3‑Q4, not revisited later
- **Commercialization risk** [recurring]: First‑sale and Europe adoption worries persisted across all quarters
- **Liquidity risk** [recurring]: Cash runway concerns appeared in every call, intensifying over time
- **Partner dependence** [resolved]: GE reliance highlighted in 2022 Q4 but absent thereafter
- **Competitive risk** [resolved]: Competitive concerns mentioned only in 2022 Q3

## Guidance path

2022 Q3:vague → 2022 Q4:maintained → 2023 Q1:vague → 2023 Q2:vague → 2023 Q3:vague → 2023 Q4:vague → 2024 Q1:vague → 2024 Q2:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/NDRA`